Franco-Vidal Valérie, Daculsi Guy, Bagot d'Arc Maurice, Sterkers Olivier, Smail Mustapha, Robier Alain, Bordure Philippe, Claros Pedro, Paiva Antonio, Darrouzet Vincent, Anthoine Emmanuelle, Bebear Jean-Pierre
ENT Department, Bordeaux 2 University Hospital , Bordeaux.
Acta Otolaryngol. 2014 Apr;134(4):358-65. doi: 10.3109/00016489.2013.859394. Epub 2014 Feb 4.
The TricOs™/MBCP(®) and fibrin sealant composite was a convenient, effective, and well-tolerated material for mastoid cavity filling and immediate reconstruction of the external auditory meatus after cholesteatoma surgery with canal wall down (CWD).
To assess the tolerance and osteointegration of a bone graft substitute, TricOs™/MBCP(®), in association with fibrin sealant for filling the mastoid cavity after cholesteatoma surgery using the CWD technique.
In this prospective observational study 57 patients with cholesteatoma suitable for CWD were recruited from April 2006 to April 2008 and followed up for 1 year. The mastoid cavity was filled with TricOs™/MBCP(®) followed by immediate reconstruction of the external auditory meatus covered with fascia temporalis and/or cartilage. The main outcome was skin tolerance assessed by a novel weighted score emphasizing long-term results. The typical weighted reference score was 1.67; skin tolerance was considered acceptable if 75% of patients had a score ≤ 1.67. Secondary outcomes were otorrhea and/or otalgia, hearing, and osteointegration assessed through computed tomography scanning at 12 months.
Forty-one patients had a complete follow-up; 34 (82.3%) patients achieved the main end point with scores ≤ 1.67. Otorrhea decreased postoperatively. No otalgia interfering with daily tasks was reported. Ossicular reconstruction was carried out in 29 patients. Absence of cochlear toxicity was confirmed by unimpaired bone conduction. Preoperative and postoperative speech audiometry results were similar. No serious adverse events were observed. Osteointegration was satisfactory with hyperdensity or intermediate density in 95% of patients at 12 months.
TricOs™/MBCP(®)与纤维蛋白密封剂复合材料是一种方便、有效且耐受性良好的材料,用于胆脂瘤手术伴外耳道后壁切除术(CWD)后乳突腔填充和外耳道即刻重建。
评估骨移植替代物TricOs™/MBCP(®)与纤维蛋白密封剂联合用于采用CWD技术的胆脂瘤手术后填充乳突腔的耐受性和骨整合情况。
在这项前瞻性观察性研究中,2006年4月至2008年4月招募了57例适合CWD的胆脂瘤患者,并随访1年。乳突腔用TricOs™/MBCP(®)填充,随后即刻用颞肌筋膜和/或软骨覆盖外耳道进行重建。主要结局是通过强调长期结果的新型加权评分评估的皮肤耐受性。典型的加权参考评分为1.67;如果75%的患者评分≤1.67,则认为皮肤耐受性可接受。次要结局是耳漏和/或耳痛、听力,以及在12个月时通过计算机断层扫描评估的骨整合情况。
41例患者完成随访;34例(82.3%)患者达到主要终点,评分≤1.67。术后耳漏减少。未报告干扰日常活动的耳痛。29例患者进行了听骨链重建。骨传导未受损证实无耳蜗毒性。术前和术后言语听力测试结果相似。未观察到严重不良事件。12个月时,95%的患者骨整合良好,表现为高密度或中等密度。